

SmartPA Criteria Proposal

Drug/Drug Class:	Antihistamines – Intranasal PDL Edit
First Implementation Date:	June 24, 2009
Proposed Date:	March 19, 2020
Prepared For:	MO HealthNet
Prepared By:	MO HealthNet/Conduent
Criteria Status:	<input type="checkbox"/> Existing Criteria <input checked="" type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

Executive Summary

Purpose: The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

Why Issue Selected: Intranasal antihistamines are FDA approved for the relief of symptoms of seasonal allergic rhinitis. Contraindications, warnings, adverse drug events, and drug interactions are similar for all products and are considered class effects apart from use in children. Astepro® (0.1%) is approved for perennial allergic rhinitis in adults and children 6 months of age and older. Astelin® (0.1%) is approved for seasonal allergic rhinitis in adults and children 5 years of age and older. Patanase® is approved for adults and children 6 years of age and older.

Total program savings for the PDL classes will be regularly reviewed.

Program-Specific Information:	Preferred Agents	Non-Preferred Agents
	<ul style="list-style-type: none"> Azelastine 0.1% (gen Astelin®) 	<ul style="list-style-type: none"> Astepro® Azelastine 0.15% (gen Astepro®) Olopatadine Patanase®

Type of Criteria: Increased risk of ADE
 Appropriate Indications

Preferred Drug List
 Clinical Edit

Data Sources: Only Administrative Databases

Databases + Prescriber-Supplied

Setting & Population

- Drug class for review: Antihistamines – Intranasal
- Age range: 6 months to adult: Astepro®
- Age range: 5 years old to adult: Astelin®
- Age range: 6 years old to adult: Patanase®

Approval Criteria

- Participant is of appropriate ages per agent **AND**
- Failure to achieve desired therapeutic outcomes with trial on 1 preferred agent
 - Documented trial period of preferred agents
 - Documented ADE/ADR to preferred agents

Denial Criteria

- Lack of adequate trial on required preferred agents
- Therapy will be denied if no approval criteria are met

Required Documentation

Laboratory Results:
MedWatch Form:

Progress Notes:
Other:

Disposition of Edit

Denial: Exception Code "0160" (Preferred Drug List)
Rule Type: PDL

Default Approval Period

1 year

References

1. Evidence-Based Medicine Analysis: "Intranasal Antihistamines", UMKC-DIC; January 2020.
2. Evidence-Based Medicine and Fiscal Analysis: "Intranasal Antihistamines – Therapeutic Class Review", Conduent Business Services, L.L.C., Richmond, VA; January 2020.
3. Lippincott, Williams, Wilkins. PDR Electronic Library, Montvale NJ; 2020.
4. USPDI, Micromedex; 2020.
5. Facts and Comparisons eAnswers (online); 2020 Clinical Drug Information, LLC.

SmartPA PDL Proposal Form

© 2020 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.